Friday, July 31, 2026

Patient in her 80s Pronounced Dead Upon Arrival Due to Lack of Medical Staff

As resident doctors continue to protest against...

HLB Therapeutics CEO: New Eye Drop Could Disrupt the Market for Rare Corneal Disease

HLB Therapeutics CEO anticipates RGN-259 could surpass Oxervate within 3 years as a simpler, cost-effective NK treatment.

Kolon Group’s Biotech Bet Faces Uncertainty as October Trial Readout Becomes Critical

Kolon TissueGene's TG-C osteoarthritis treatment failed its first U.S. Phase 3 trial, raising doubts about the biotech's future.

Tag: U.K.

North KoreaKoreaKimMilitaryAISouth KoreamarketrelationsInternational

No posts to display

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.